Filing Details

Accession Number:
0001179110-14-002577
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-02-12 15:01:22
Reporting Period:
2014-02-11
Filing Date:
2014-02-12
Accepted Time:
2014-02-12 15:01:22
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1586105 Egalet Corp EGLT Pharmaceutical Preparations (2834) 463575334
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1030575 Francois Jean Formela 460 East Swedesford Road
Suite 1050
Wayne PA 19087
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-02-11 833,098 $0.00 833,098 No 4 C Indirect By Atlas Venture Fund
Common Stock Acquisiton 2014-02-11 863,754 $0.00 1,696,852 No 4 C Indirect By Atlas Venture Fund
Common Stock Acquisiton 2014-02-11 30,000 $0.00 1,726,852 No 4 X Indirect By Atlas Venture Fund
Common Stock Acquisiton 2014-02-11 298,083 $6.00 2,024,935 No 4 C Indirect By Atlas Venture Fund
Common Stock Acquisiton 2014-02-11 85,620 $6.00 2,110,555 No 4 C Indirect By Atlas Venture Fund
Common Stock Acquisiton 2014-02-11 41,667 $12.00 2,152,222 No 4 P Indirect By Atlas Venture Fund
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect By Atlas Venture Fund
No 4 C Indirect By Atlas Venture Fund
No 4 X Indirect By Atlas Venture Fund
No 4 C Indirect By Atlas Venture Fund
No 4 C Indirect By Atlas Venture Fund
No 4 P Indirect By Atlas Venture Fund
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A-1 Preferred Stock Disposition 2014-02-11 833,098 $0.00 833,098 $0.00
Common Stock Series B Preferred Stock Disposition 2014-02-11 863,754 $0.00 863,754 $0.00
Common Stock Warrants Disposition 2014-02-11 30,000 $0.00 30,000 $0.00
Common Stock Subordinated Convertible Debt Disposition 2014-02-11 0 $0.00 298,083 $6.00
Common Stock Senior Convertible Debt Disposition 2014-02-11 0 $0.00 85,620 $6.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 X Indirect
0 No 4 C Indirect
0 No 4 C Indirect
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 308,727 Indirect By Egalet A/S
Footnotes
  1. The reporting person is Egalet A/S, a corporation. Atlas Venture Fund VII, L.P. ("Atlas Venture Fund") is a 23.9% equityholder of Egalet A/S. Atlas Venture Associates VII, L.P. ("Atlas Venture Associates") is the general partner of Atlas Venture Fund, and Atlas Venture Associates VII, Inc. ("Atlas Venture Inc.") is the general partner of Atlas Venture Associates. Dr. Formela is a director of Atlas Venture Inc. and therefore may be deemed to share the right to direct the voting and dispositive control of shares held by Atlas Venture Fund. Dr. Formela disclaims beneficial ownership of any such securities except to the extent of his proportionate pecuniary interest therein, and this report shall not be deemed an admission that Dr. Formela is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
  2. The reporting person is Atlas Venture Fund. Atlas Venture Associates is the general partner of Atlas Venture Fund, and Atlas Venture Inc. is the general partner of Atlas Venture Associates. Dr. Formela is a director of Atlas Venture Inc. and therefore may be deemed to share the right to direct the voting and dispositive control of shares held by Atlas Venture Fund. Dr. Formela disclaims beneficial ownership of any such securities except to the extent of his proportionate pecuniary interest therein, and this report shall not be deemed an admission that Dr. Formela is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
  3. The Series A-1 Preferred Stock automatically converted into Egalet Corporation common stock on a 1-for-1 basis immediately prior to the consummation of Egalet Corporation's initial public offering.
  4. The Series B Preferred Stock automatically converted into Egalet Corporation common stock on a 1-for-1 basis immediately prior to the consummation of Egalet Corporation's initial public offering.
  5. The warrants were automatically exercised into Egalet Corporation common stock immediately prior to the consummation of the Egalet Corporation's initial public offering on a 1-for-1 basis, pursuant to Atlas Venture Fund's purchase of a specified minimum amount of common stock in such offering.
  6. The subordinated convertible debt automatically converted into Egalet Corporation common stock immediately prior to the consummation of Egalet Corporation's initial public offering, based on a conversion price equal to 50% of the per share price in such offering, which was $12 per share.
  7. The senior convertible debt automatically converted into Egalet Corporation common stock immediately prior to the consummation of Egalet Corporation's initial public offering, based on a conversion price equal to 50% of the per share price in such offering, which was $12 per share.